

Lifeblood for growth



New medical patents to create biological matter

Business growth can come, amongst other things, from the decision to change identity and market position as a result of innovation-driven development.

This is what happened to Meditalia srl, based in Lombardy, Italy. On the strength of its long experience in the biomedical field, the company recently signed an important agreement with the Italian National Blood Center to work on the Nupla project. The focus will be on new reagents, medical devices, blood derivatives and medicines obtained from placental blood.

The collaboration has been a major driver in the development of Meditalia, which came on the heels of a period spent focusing on innovative patents in the medical field - in collaboration with the Ca' Granda Ospedale Maggiore Policlinico" Foundation in

Milan - to create new applications in clinical therapy. "We acquired a patent granted in the US and Europe for the preparation of a platelet gel from cord blood," Meditalia CEO Giovanni Mazzaro explained.

"Taking this as our starting point, we patented a new device able to bring the benefits of this biological matter to patients. Under the agreement signed with CNS, we now hope to create a value stream from the industrial production of growth-factor based medical aids." The agreement also comprises cord blood banks in Italy. "This pilot project aims to show how effective the new material can be in the treatment of some diseases, especially chronic ones."

The company has set its sights on Europe too, with an agreement already signed with the Banc de Sang y Teixits in Barcelona, which



GIOVANNI MAZZARO

has strong links with manufacturing. Meditalia has boosted its team significantly to manage this new process.

Professor Paolo Rebullà - a leading international blood component expert - has been brought on-board and professor Claudio Migliaresi, a renowned European scientist in the biomatter field, has become involved. A start-up enterprise was formed - Episkey - owned by Meditalia, "to create a value stream from products obtained from cord blood," Rebullà explained.

For every hundred donations, only ten contain a sufficient number of stem cells, so we are studying alternative ways of using donations which would otherwise be eliminated." 

